StreetInsider.com News Articles

Truist Securities Starts Oranogenesis Holdings (ORGO) at Hold

Thu, 28 May 2026 06:06:05 -0400

Truist Securities analyst Ravi Misra initiates coverage on Oranogenesis Holdings (NASDAQ: ORGO) with a Hold rating and a price target of $3.00.

The analyst comments "Initiating with HOLD and $3 PT on ORGO, a leader in skin substitutes in the wound care market. Reimbursement changes are driving structural shifts across care settings in '26, and impacting all players as stakeholders navigate a new payment paradigm. A shakeout in the space could benefit ORGO as smaller players exit the market due to unfavorable economics, but we see limited NT rev upside (recently lowered guidance contemplates a worse decline in '26 than prior).

Truist Securities Starts Oranogenesis Holdings (ORGO) at Hold

Thu, 28 May 2026 06:06:05 -0400

Truist Securities analyst Ravi Misra initiates coverage on Oranogenesis Holdings (NASDAQ: ORGO) with a Hold rating and a price target of $3.00.

BTIG Downgrades Oranogenesis Holdings (ORGO) to Neutral

Fri, 08 May 2026 05:34:09 -0400

(Updated - May 8, 2026 5:34 AM EDT)

BTIG analyst Ryan Zimmerman downgraded Oranogenesis Holdings (NASDAQ: ORGO) from Buy to Neutral.

The analyst comments "We downgrade ORGO shares to Neutral and remove our PT following 1Q26 results. Investors knew that results would be weak given the changes in reimbursement within Advanced Wound Care but the recovery (if there is to be one) is taking longer to play out with limited clarity as to when it may actually occur. Multiple factors (including the removal of LCDs, CMS' wastage policy, the preliminary WISeR model, etc) have all materially slowed the market, creating confusion, limiting

BTIG Downgrades Oranogenesis Holdings (ORGO) to Neutral

Fri, 08 May 2026 05:34:09 -0400

(Updated - May 8, 2026 5:34 AM EDT)

BTIG analyst Ryan Zimmerman downgraded Oranogenesis Holdings (NASDAQ: ORGO) from Buy to Neutral.

Organogenesis Holding (ORGO) Misses Q1 EPS by 15c

Thu, 07 May 2026 17:46:07 -0400

Organogenesis Holding (NASDAQ: ORGO) reported Q1 EPS of ($0.44), $0.15 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $37.2 million versus the consensus estimate of $43.3 million.

For earnings history and earnings-related data on Organogenesis Holding (ORGO) click here.

Form 10-Q Organogenesis Holdings For: Mar 31

Thu, 07 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260507/26453716.html

Form 10-Q Organogenesis Holdings For: Mar 31

Thu, 07 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260507/26453716.html

Form 8-K Organogenesis Holdings For: May 07

Thu, 07 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260507/26453380.html

Form 8-K Organogenesis Holdings For: May 07

Thu, 07 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260507/26453380.html

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Results Summary:

Net revenue of $36.3 million for the first quarter of 2026, a decrease of $50.4 million compared to net revenue of $86.7 million for the first quarter of 2025. Net

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

First Quarter 2026 Financial Results Summary:

Net revenue of $36.3 million for the first quarter of 2026, a decrease of $50.4 million compared to net revenue of $86.7 million for the first quarter of 2025. Net

Form ARS Organogenesis Holdings For: Dec 31

Thu, 30 Apr 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260430/26408585.html

Form ARS Organogenesis Holdings For: Dec 31

Thu, 30 Apr 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260430/26408585.html

Form DEF 14A Organogenesis Holdings For: Jun 15

Thu, 30 Apr 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260430/26408426.html

Form DEF 14A Organogenesis Holdings For: Jun 15

Thu, 30 Apr 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260430/26408426.html

Organogenesis completes FDA submission for knee arthritis treatment

Tue, 28 Apr 2026 16:30:57 -0400

Organogenesis Holdings Inc. (NASDAQ: ORGO) completed its rolling Biologics License Application submission to the Food and Drug Administration for ReNu, a treatment for symptomatic knee osteoarthritis, according to a company statement.

The company initiated the rolling BLA submission in December 2025 with non-clinical modules and has now completed the application with clinical and chemistry, manufacturing, and controls modules.

"We are pleased to complete the BLA submission for ReNu, which represents a significant milestone in our drive to bring a new regenerative therapy to knee OA patients," said Patrick Bilbo, Chief Operating Officer of Organogenesis.

ReNu is a cryopreserved, amniotic suspension allograft that contains

Organogenesis completes FDA submission for knee arthritis treatment

Tue, 28 Apr 2026 16:30:57 -0400

The company initiated the rolling BLA submission in December 2025 with non-clinical modules and has now completed the application with clinical and chemistry, manufacturing, and controls modules.

ReNu is a cryopreserved, amniotic suspension allograft that contains

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

Tue, 28 Apr 2026 16:30:00 -0400

If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain

CANTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the completion of a rolling Biologics License Application (BLA) submission to the Food and Drug Administration (FDA) for ReNu^®, a cryopreserved, amniotic suspension allograft developed for the management of symptomatic knee osteoarthritis (OA).

“We are pleased to complete the BLA

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

Tue, 28 Apr 2026 16:30:00 -0400

If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain

“We are pleased to complete the BLA

Form 4 Organogenesis Holdings For: Jan 10 Filed by: Grow Brian

Fri, 24 Apr 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260424/26367823.html

Form 4 Organogenesis Holdings For: Jan 10 Filed by: Grow Brian

Fri, 24 Apr 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260424/26367823.html

Organogenesis achieves primary endpoint in diabetic foot ulcer trial

Tue, 07 Apr 2026 03:59:09 -0400

Organogenesis Holdings Inc. (NASDAQ: ORGO) announced completion of a randomized controlled trial evaluating its PuraPly AM product for treating diabetic foot ulcers. The study met its primary endpoint, demonstrating statistically significant wound closure at 12 weeks compared to standard care alone.

The multi-center trial enrolled 170 patients and compared PuraPly AM plus standard of care against standard care alone for non-healing diabetic foot ulcers. The treatment group achieved significantly better wound closure rates with a p-value of less than 0.0477.

"We are pleased to report primary endpoint achievement in this important study underscoring the clinical efficacy of PuraPly AM in the management

Organogenesis achieves primary endpoint in diabetic foot ulcer trial

Tue, 07 Apr 2026 03:59:09 -0400

"We are pleased to report primary endpoint achievement in this important study underscoring the clinical efficacy of PuraPly AM in the management

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Mon, 06 Apr 2026 19:02:29 -0400

Statistically significant (p<0.0477) DFU wound closure at 12 weeks
RCT compared PuraPly®AM plus standard of care to standard of care alone
Results strengthen existing clinical evidence supporting future coverage

CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the completion of a randomized controlled trial (RCT) evaluating PuraPly®AM plus standard of care (SOC) versus SOC alone in the management of

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Mon, 06 Apr 2026 19:02:29 -0400

Statistically significant (p<0.0477) DFU wound closure at 12 weeks
RCT compared PuraPly®AM plus standard of care to standard of care alone
Results strengthen existing clinical evidence supporting future coverage